Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

Brief Title

Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

Official Title

Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease

Brief Summary

      The purpose of this study is to determine whether thorough analytical evaluation is useful to
      diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.
    

Detailed Description

      The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis,
      hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate
      dihydrate (CPPD) deposition disease is uncertain.

      Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid
      arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively
      followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase,
      thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined
      in all patients.
    


Study Type

Observational




Condition

Chondrocalcinosis



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

240

Start Date

January 1997

Completion Date

December 2006


Eligibility Criteria

        Inclusion Criteria:

          -  Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

        Exclusion Criteria:

          -  Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or
             with psoriasis.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

José M Pego-Reigosa, MD, PhD, , 

Location Countries

Spain

Location Countries

Spain

Administrative Informations


NCT ID

NCT00453128

Organization ID

SGR1



Study Sponsor

Sociedade Galega de Reumatoloxía


Study Sponsor

José M Pego-Reigosa, MD, PhD, Principal Investigator, Meixoeiro Hospital, Vigo (Pontevedra) SPAIN


Verification Date

March 2007